ClinicalTrials.gg
Active, not recruitingNCT05975021SEISMiC-CUpdated Aug 20, 2025

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

A Phase 1/2 interventional study of Istaroxime and Placebo in Cardiogenic Shock, sponsored by Windtree Therapeutics. Active, not recruiting at 15 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Windtree Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental status, mottled and cool extremities, and delayed capillary refill, as well as signs of congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to organs) which frequently require support with rescue therapies including inotropes, vasopressors, or mechanical devices.

Windtree Therapeutics, Inc. has been studying istaroxime, which has the potential to treat patients in this condition without some of the disadvantages of existing therapies being used to treat patients with acute heart failure and CS.

Participants enrolled in this trial will receive standard of care (SoC) therapy for heart failure and CS. Additionally, half of the participants will be randomly chosen to receive istaroxime. Istaroxime has the potential to increase blood pressure and improve cardiac function.

02

Conditions studied

  • Cardiogenic Shock

Browse trials for

03

In context

Shock, Cardiogenic

296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Windtree Therapeutics is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form (ICF);
  • Clinical presentation consistent with SCAI Stage C cardiogenic shock caused by ADHF and meeting the criteria in below table;
  • Admitted to ICU within 36 hours prior to randomization with congestion on chest x-ray or lung ultrasound and BNP ≥ 400 pg/mL or NT-proBNP ≥ 1400 pg/mL;
  • Males and females, 18 to 85 years of age (inclusive);
  • History of (LVEF) ≤ 40%;
  • Persistent hypotension defined as SBP between 70 and 90 mmHg for 2 readings with concomitant signs of hypoperfusion;
  • Echocardiogram during initial hospitalization confirming ejection fraction ≤ 40% and no evidence of other pathology to confound interpretation of cardiac physiology (eg, pericardial effusion).

Table: Definition of SCAI Stage C Required for Inclusion. These criteria must be present at screening or prior to screening in patients actively treated by vasoactive agents or/and inotropes concomitantly (at the same time)

Must have at Least One of:

  • Hypoperfusion: Venous Lactate ≥ 2 mmol/L, urine output \< 30 mL/hour, cold and clammy or acute alteration in mental status.
  • Hemodynamic Instability: SBP 70-90 mmHg, cardiac index \< 2.2 L/min/meter2 and PCW > 15 mmHg

Without Any Of:

  • Venous lactate > 5 mmol/L
  • Worsening clinical status despite initial therapy (e.g., worsening hemodynamics, worsening renal or liver function)
  • >500 U/L (8.333 µkat/L)

Exclusion criteria

Exclusion Criteria:

  • Patient is in SCAI B (BP increased above 90 mmHg despite no vasoactive or inotrope therapy) or SCAI D (continuously deteriorating BP and hypoperfusion despite vasoactive or inotrope therapy);
  • Lactate \< 2 mmol/L (unless the patient meets the criteria in bullet 2 of Table 5-1) or lactate > 5 mmol/L prior to randomization;
  • Cardiogenic shock due to any other condition besides acute decompensation of chronic heart failure;
  • Any of the following in the past 30 days: acute coronary syndrome, coronary revascularization, MI, CABG, or percutaneous coronary intervention;
  • Current (within 6 hours of screening) or anticipated need for treatment with renal support including ultrafiltration, or mechanical circulatory, ventilatory or renal support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) such as persistent hypoperfusion and hypotension;
  • History of heart transplant or UNOS priority 1a heart transplant listing
  • Ongoing treatment with digoxin (if digoxin was stopped before signing the ICF and the digoxin plasma level is \< 0.5 ng/ml, the patient may be enrolled);
  • Severe renal impairment ( \< 30 ml/min, calculated by the MDRD formula);
  • to the trial medication and its (including known lactose hypersensitivity) or any related medication;
  • Stroke or within 3 months;
  • Severe obstructive valvular lesions including severe aortic or mitral stenosis;
  • Primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease;
  • Admission for AHF triggered primarily by a correctable etiology such as significant arrhythmia (inclusive of atrial fibrillation as the main reason for admission), infection, severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of , planned admission for device implantation, or over-diuresis as a cause of hypotension;
  • Pericardial constriction or active pericarditis;
  • Significant ventricular arrhythmia prior to screening (such as sustained ventricular tachycardia or ventricular fibrillation) or implantable cardioverter defibrillator (ICD) shock within the past month or history of sudden death within 6 months;
  • Cardiac resynchronization therapy (CRT), ICD, or pacemaker implantation within the past month;
  • Uncontrolled arrythmia;
  • Sustained hypotension (SBP \< 70 mmHg) for at least 30 minutes from the time of arrival to the hospital;
  • Systolic BP > 120 mmHg during the hour prior to randomization
  • Cor pulmonale or other causes of isolated right-sided HF or not related to left ventricular dysfunction;
  • Acute respiratory distress syndrome;
  • Suspected sepsis; fever > 38° or active infection requiring IV antimicrobial treatment;
  • Body weight \< 40 kg or ≥ 150 kg;
  • Laboratory exclusions:

    1. \< 9 g/dl,
    2. count \< 100,000/µl,
    3. Serum potassium > 5.3 mmol/l or \< 3.5 mmol/l;
  • A \< 3 months based on the judgment of the investigator;
  • Severe pulmonary or thyroid disease;
  • Pregnant, planning on becoming pregnant, or currently breast-feeding;
  • Ongoing drug or alcohol abuse;
  • Participation in another interventional trial within the past 30 days.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Istaroxime

    Istaroxime delivered as an IV infusion via a syringe pump. Dosage regime is 1.0 µg/kg/min for 6 hours, 0.5 µg/kg/min for 42 hours. Total duration 48 hours.

    Drug: Istaroxime

  • Placebo comparator
    Placebo

    Placebo (lactose) delivered as an IV infusion via a syringe pump. Total duration 48 hours.

    Drug: Placebo

Interventions

  • IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.

    Also known as: PST2744

  • DrugPlacebo

    IV infusion via a syringe pump. Total duration 48 hours.

    Also known as: Lactate

06

What researchers measure

Primary outcomes

  1. SBP AUC 0-6

    Systolic blood pressure (SBP) area under the curve (AUC) from start of infusion to 6 hours

    Time frame: Start of infusion to 6 hours

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: Yes — The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement between Windtree and participating institutions. The publication or presentation of any study results shall comply with all applicable privacy laws, including but not limited to HIPAA. This trial will be registered in the ClinicalTrials.gov and the CTIS databases, and results information from this trial will be submitted to both. In addition, every attempt will be made to publish results in peer-reviewed journals.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: 6 months after study end.

Access criteria: Mutual written agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jul 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 3, 2023
StartActual
Jun 1, 2024
Primary completionActual
Jul 28, 2025
CompletionEst.
Aug 31, 2026
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05975021
Lead sponsor
Windtree Therapeutics
Responsible party
Sponsor
First posted
Aug 3, 2023
Start date
Jun 1, 2024
Primary completion
Jul 28, 2025
Completion
Aug 31, 2026 (estimated)
Last update
Aug 20, 2025

Study contacts

Steven G Simonson, MD
study director · Windtree Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istaroxime

Start the discussion